TY - JOUR
T1 - Immune checkpoint inhibitors in neuroendocrine tumors
T2 - A single institution experience with review of literature
AU - Chauhan, Aman
AU - Horn, Millicent
AU - Magee, Gray
AU - Hodges, Kurt
AU - Evers, Mark
AU - Arnold, Susanne
AU - Anthony, Lowell
N1 - Publisher Copyright:
© Chauhan et al.
PY - 2018
Y1 - 2018
N2 - This unique case series and review of literature suggests that immune checkpoint inhibitors may have clinical activity in neuroendocrine tumors. Objective: Summarize advances of immuno-oncology in neuroendocrine tumors with the help of a case series. Design: Case series and review of literature. Intervention or Exposure: The patients were treated with immune checkpoint inhibitors (pembrolizumab or nivolumab). Main Outcome(s) and Measures(s): Life expectancy, quality of life, disease progression. Results: Maximum durable response of 16 months in one of the patients so far. All patients showed improvement in quality of life before disease progression. Two out of four are still on therapy. None of the patients experienced immune checkpoint inhibitor associated side-effects. All patients had failed standard of care therapy prior to the initiation of immune checkpoint inhibitors and were on the verge of hospice. Conclusions: Immune checkpoint inhibitors have revolutionized cancer management and the last 5 years have seen a rapid expansion in the indications for this class of drug. Neuroendocrine tumors, unfortunately, have been slow to catch on to the immuno-oncology, partly due to difficulties in establishing relevant preclinical neuroendocrine tumors models for immune-oncology studies. In this manuscript, we review the current status of immunotherapy in neuroendocrine tumors.
AB - This unique case series and review of literature suggests that immune checkpoint inhibitors may have clinical activity in neuroendocrine tumors. Objective: Summarize advances of immuno-oncology in neuroendocrine tumors with the help of a case series. Design: Case series and review of literature. Intervention or Exposure: The patients were treated with immune checkpoint inhibitors (pembrolizumab or nivolumab). Main Outcome(s) and Measures(s): Life expectancy, quality of life, disease progression. Results: Maximum durable response of 16 months in one of the patients so far. All patients showed improvement in quality of life before disease progression. Two out of four are still on therapy. None of the patients experienced immune checkpoint inhibitor associated side-effects. All patients had failed standard of care therapy prior to the initiation of immune checkpoint inhibitors and were on the verge of hospice. Conclusions: Immune checkpoint inhibitors have revolutionized cancer management and the last 5 years have seen a rapid expansion in the indications for this class of drug. Neuroendocrine tumors, unfortunately, have been slow to catch on to the immuno-oncology, partly due to difficulties in establishing relevant preclinical neuroendocrine tumors models for immune-oncology studies. In this manuscript, we review the current status of immunotherapy in neuroendocrine tumors.
KW - Immune check point inhibitor
KW - Neuroendocrine tumors
UR - http://www.scopus.com/inward/record.url?scp=85041420650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041420650&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.23753
DO - 10.18632/oncotarget.23753
M3 - Article
C2 - 29507655
AN - SCOPUS:85041420650
SN - 1949-2553
VL - 9
SP - 8801
EP - 8809
JO - Oncotarget
JF - Oncotarget
IS - 10
ER -